Publication de Nicole Delepine : Treatment of pelvic Ewing's sarcoma with multidisciplinary treatment.

Nicole delépine, le site officiel English Version Version Française
Accueil Site officiel ACCUEIL
Accueil du site officiel de Nicole Delepine
publication cancérologue réputé nicole delepine ostéosarcome
sarcome ewing publications du docteur nicole delepine
Publié sur : Page 74, CCOS abstracts in Sarcoma. Ed. Taylor et Francis. Volume 5, n°1 - 2001
Voir la version PDF de cette publication : Document PDF | Publication sur le site du média : Document www
Treatment of pelvic Ewing's sarcoma with multidisciplinary treatment.
G. Delépine, F. Delépine, S. Alkallaf, H. Cornille, T. Sokolov, Nicole Delepine

Treatment Of Pelvic Ewing's Sarcoma With Multidisciplinary Treatment

Despite the improved survival of patients with Ewing's sarcoma, pelvic location remains a bad prognostic factor.
This retrospective analysis tries to point out the reasons of such a situation, and to evaluate the impact of modem comprehensive approach on prognosis.

Material and methods:
From February 1977 to June 1998, 53 patients have been treated by our group for Ewing's sarcoma ofpelvic bones. Thirty-two were males, 21 females, aged 6± 35 years
(median, 16.3 years). At first screening, 15 patients had already metastases and 38 presented with localised disease.
Treatment included chemotherapy for all patients according to the current protocol at the time of presentation: four drugs (Vincristine± Dactinomycin± Cyclophosphamide± Doxorubicin), five drugs (Vincristine± Doxorubicin± Cyclophosphamide± Dactinomycine +ifosfamide) or six drugs association (Ifosfamide± Vincristine± Doxorubicin± Cyclophosphamide± Dactinomycine + Etoposide or Cisplatinium).
Local treatment used radiotherapy alone for 24 patients, surgery alone in 18 and a combination in 11.
All patients have been followed up every 3 months for 2 years, every 6 months for 2 other years, and then yearly.

With a median follow-up of 10 years, the 5-year actuarial event free survival rate for all patients is 31%; 13% for primary metastatic patients and 40% for patients seen with localised disease (p < 0.001). In primary localised tumor, the major prognostic factors
are the adequacy of surgical resection (p < 0.01) and the high dose intensity of chemotherapy, particularly during the induction (p < 0.05).
Patients treated by radiotherapy had a 44% risk of local recurrence, 17% life expectancy, and a 13 month median survival compared with an 80% life expectancy and 80 month median survival for patients after wide resection.

(1) Primary metastatic patients require a new approach.
(2) Early wide resection of the primary and adequate dose intensity of a six-drug chemotherapy gives the best results in pelvic Ewing's despite large tumoral volume or even incomplete response to pre-operative chemotherapy.

publications médicales

sarcome d'ewing
nicole delepine cancer tumeur ostéosarcome
Facebook Tweeter